Bicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Rating of “Moderate Buy” by Analysts

Bicycle Therapeutics plc (NASDAQ:BCYC) has received an average recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $44.56.

Several analysts recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday. Royal Bank of Canada assumed coverage on Bicycle Therapeutics in a research note on Friday, September 6th. They set an “outperform” rating and a $35.00 price objective for the company. B. Riley cut shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $33.00 to $28.00 in a research note on Wednesday, August 7th. Oppenheimer reaffirmed an “outperform” rating and issued a $48.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, August 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $38.00 target price on shares of Bicycle Therapeutics in a research report on Monday.

Bicycle Therapeutics Trading Down 0.3 %

NASDAQ:BCYC opened at $26.96 on Friday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -6.06 and a beta of 0.90. Bicycle Therapeutics has a 52 week low of $12.54 and a 52 week high of $27.82. The company has a quick ratio of 14.77, a current ratio of 14.77 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average price is $22.63 and its 200-day moving average price is $22.97.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Tuesday, August 6th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.33. The business had revenue of $9.36 million during the quarter, compared to analyst estimates of $6.13 million. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. The firm’s quarterly revenue was down 17.9% on a year-over-year basis. On average, equities research analysts forecast that Bicycle Therapeutics will post -3.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,194 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $19.64, for a total transaction of $62,730.16. Following the sale, the chief executive officer now directly owns 384,076 shares of the company’s stock, valued at $7,543,252.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 4,555 shares of company stock valued at $89,460 in the last three months. Corporate insiders own 8.50% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP raised its position in Bicycle Therapeutics by 176.1% in the 1st quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock worth $123,076,000 after purchasing an additional 3,152,433 shares during the period. Westfield Capital Management Co. LP bought a new position in shares of Bicycle Therapeutics during the fourth quarter valued at approximately $16,585,000. Avoro Capital Advisors LLC bought a new stake in Bicycle Therapeutics during the 2nd quarter valued at about $14,168,000. Perceptive Advisors LLC bought a new position in Bicycle Therapeutics in the 2nd quarter worth about $11,577,000. Finally, Armistice Capital LLC grew its stake in Bicycle Therapeutics by 53.6% in the 4th quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock worth $27,771,000 after acquiring an additional 536,000 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.